PUBLICATIONS
Select 33 from 168
IFN-γ–resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models
Bailey, Takei, Escobar, et al, Science Translational Medicine, 2025
Secretion of a VEGF-blocking scFv enhances CAR T-cell potency
Supper, Donner, et al... Leick Clinical Cancer Research 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Blumenberg, et al... Frigault, Blood, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
Frigault et al, Blood Advances, 2025
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML
Silva, et al... Leick, Blood, 2025
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics
Korell et al, Science Translational Medicine, 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault, Graham, Berger, et al, Blood, 2024
Stealth transgenes enable CAR-T cells to evade host immune responses
Grauwet et al, Journal for Immunotherapy of Cancer, 2024
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells
Elsallab et al, Transplantation and Cellular Therapy, 2024
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Choi et al, New England Journal of Medicine, 2024
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood
Lee et al, Cytometry B Clinical Cytometry, 2024
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Wehrli, Guinn, Birocchi et al, Clinical Cancer Research, 2024
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Larson et al, Nature Communications, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Ra2 are effective against heterogeneous glioblastoma
Schmidts et al, Neuro-Oncology Advances, 20203
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, Leick, Maurer, Gohil et al,
Nature Medicine 2022
Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault et al, Blood Advances 2022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick et al, Cancer Cell 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumors.
Larson et al, Nature 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault et al, Blood 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey et al, Blood Cancer Discovery 2022
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli et al, Journal for Immunotherapy of Cancer 2022
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.
Jan et al, Science Translational Medicine 2021
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts et al, Journal for Immunotherapy of Cancer 2020
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs et al, Molecular Therapy 2020
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts et al, Blood Advances 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj et al, Clinical Cancer Research 2019
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
Choi et al, Nature Biotechnology 2019
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
Frigault et al, Blood 2019
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Boroughs et al, JCI Insight 2019
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
Scarfò et al, Blood 2018